SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-06-30 was 22.02K shares, a 331.69% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2016 was 1.29M shares, a 54.59% decline from fiscal 2015.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 2.83M shares, a 67.01% increase from fiscal 2014.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 1.69M shares, a 25.80% decline from fiscal 2013.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2013 was 2.28M shares, a 79.90% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-05 | 0.00 shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | ||||
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-06 | 22.02K shares derived: sum of 2 quarters · filed 2026-08-05 | 488.19K shares 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 22.02K shares 10-Q · filed 2026-08-05 | 488.19K shares 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 466.18K shares 10-Q · filed 2026-05-06 | ||||
| 2024-09-30 | 6.44K shares 10-Q · filed 2025-11-06 | 11.54K shares derived: sum of 2 quarters · filed 2025-11-06 | 327.92K shares 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 5.10K shares 10-Q · filed 2025-08-06 | 321.48K shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 316.38K shares 10-Q · filed 2025-05-06 | ||||
| 2023-09-30 | 50.88K shares 10-Q · filed 2024-11-06 | 105.45K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.14M shares 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 54.58K shares 10-Q · filed 2024-08-07 | 1.08M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 1.03M shares 10-Q · filed 2024-05-01 | ||||
| 2022-09-30 | 127.10K shares 10-Q · filed 2023-11-01 | 334.68K shares derived: sum of 2 quarters · filed 2023-11-01 | 1.63M shares 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | 207.58K shares 10-Q · filed 2023-08-02 | 1.50M shares 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | 1.29M shares 10-Q · filed 2023-05-02 | ||||
| 2021-09-30 | 91.20K shares 10-Q · filed 2022-11-02 | 163.31K shares derived: sum of 2 quarters · filed 2022-11-02 | 1.52M shares 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | 72.11K shares 10-Q · filed 2022-08-02 | 1.43M shares 10-Q · filed 2022-08-02 | |||
| 2017-06-30 | 3.30M shares 10-Q · filed 2022-05-04 | ||||
| 2016-12-31 | 1.29M shares 10-K · filed 2017-02-28 | ||||
| 2015-12-31 | 153.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | 855.37K shares derived: sum of 2 quarters · filed 2017-02-28 | 1.22M shares derived: sum of 3 quarters · filed 2017-02-28 | 2.83M shares 10-K · filed 2017-02-28 | |
| 2015-09-30 | 702.07K shares 10-Q · filed 2015-11-05 | 1.07M shares derived: sum of 2 quarters · filed 2015-11-05 | 2.68M shares 10-Q · filed 2015-11-05 | 2.83M shares derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | 367.17K shares 10-Q · filed 2015-08-06 | 1.97M shares 10-Q · filed 2015-08-06 | 2.13M shares derived: sum of 3 quarters · filed 2017-02-28 | 2.37M shares derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-03-31 | 1.61M shares 10-Q · filed 2015-05-07 | 1.76M shares derived: sum of 2 quarters · filed 2017-02-28 | 2.00M shares derived: sum of 3 quarters · filed 2017-02-28 | 2.12M shares derived: sum of 4 quarters · filed 2017-02-28 | |
| 2014-12-31 | 154.47K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | 391.52K shares derived: sum of 2 quarters · filed 2017-02-28 | 509.30K shares derived: sum of 3 quarters · filed 2017-02-28 | 1.69M shares 10-K · filed 2017-02-28 | |
| 2014-09-30 | 237.05K shares 10-Q · filed 2015-11-05 | 354.82K shares derived: sum of 2 quarters · filed 2015-11-05 | 1.54M shares 10-Q · filed 2015-11-05 | 1.76M shares derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-06-30 | 117.77K shares 10-Q · filed 2015-08-06 | 1.30M shares 10-Q · filed 2015-08-06 | 1.52M shares derived: sum of 3 quarters · filed 2016-02-25 | 1.83M shares derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-03-31 | 1.19M shares 10-Q · filed 2015-05-07 | 1.41M shares derived: sum of 2 quarters · filed 2016-02-25 | 1.71M shares derived: sum of 3 quarters · filed 2016-02-25 | 3.23M shares derived: sum of 4 quarters · filed 2016-02-25 | |
| 2013-12-31 | 220.32K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | 529.55K shares derived: sum of 2 quarters · filed 2016-02-25 | 2.04M shares derived: sum of 3 quarters · filed 2016-02-25 | 2.28M shares 10-K · filed 2016-02-25 | |
| 2013-09-30 | 309.23K shares 10-Q · filed 2014-11-06 | 1.82M shares derived: sum of 2 quarters · filed 2014-11-06 | 2.06M shares 10-Q · filed 2014-11-06 | 2.41M shares derived: sum of 4 quarters · filed 2015-02-26 | |
| 2013-06-30 | 1.51M shares 10-Q · filed 2014-08-07 | 1.75M shares 10-Q · filed 2014-08-07 | 2.10M shares derived: sum of 3 quarters · filed 2015-02-26 | 2.82M shares derived: sum of 4 quarters · filed 2015-02-26 | |
| 2013-03-31 | 242.32K shares 10-Q · filed 2014-05-08 | 590.00K shares derived: sum of 2 quarters · filed 2015-02-26 | 1.31M shares derived: sum of 3 quarters · filed 2015-02-26 | ||
| 2012-12-31 | 347.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | 1.06M shares derived: sum of 2 quarters · filed 2015-02-26 | 1.27M shares 10-K · filed 2015-02-26 | ||
| 2012-09-30 | 715.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | 921.79K shares 10-Q · filed 2012-11-07 | |||
| 2012-06-30 | 206.41K shares 10-Q · filed 2012-08-07 | ||||
| 2011-12-31 | 1.60M shares 10-K · filed 2014-03-03 | ||||
| 2010-12-31 | 601.23K shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |